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Rogers Brambell (1901–1970), the father
of the field of FcRn biology, was by all
accounts a scientist of great imagination
and insight, one whom we would look to,
were he available, for opinions on our cur-
rent scientific direction. Were we to ask
him, in a moment of fantasy, to review
recent progress in his field, we think he
would say that we have gone astray, that
we have become confused about what he
thought was a critical issue. Specifically, we
have ignored the important point of where
in the cell FcRn expresses its specificity for
ligand, either on or in the cell; and rather
than deal directly with that basic issue, we
have side-stepped the question, leaving it
unanswered, and in fact have implied that
it is not a critical question.
His last comment on the issue, in his
1970 tome, published the year he died,
was that specificity of the receptor for lig-
and in tissues like the yolk sac was deter-
mined intracellularly in what we now know
to be acidic vesicles of the pinocytic traf-
ficking pathway. Thus receptor-bound lig-
and destined for transcellular transport was
separated effectively from free ligand des-
tined for lysosomal degradation. To others,
however, the situation seemed more com-
plex, and alternate views were expressed.
In the gut of the neonatal rat or mouse,
the receptor was found expressed on the
epithelial surface where under the influ-
ence of the low pH of gut contents it
bound with high affinity to the IgG in
maternal milk, and both the receptor and
its bound ligand were endocytosed, the
ligand ultimately reaching its destination,
the fetal circulation. Receptor specificity
for ligand, thus, was conferred at the cell
surface.
For receptor–ligand specificity to be dic-
tated at two different sites depending on
the nature of the tissue seemed far-fetched
to some, and additional observations were
brought to bear. The low pH of gut con-
tents was questioned. Gut pH had been
measured only once, with litmus paper,
and the observation was never repeated.
As well, the relevance of surface-expressed
receptor was questioned. It became appar-
ent that only a fraction of total cell recep-
tor, probably <1%, is found on the sur-
face of the cell. This low level of surface
expression is likely a vestige of the exo-
cytosis step of IgG transport and not an
essential component of the ligand-uptake
pathway. Further, an experiment expressly
designed to evaluate the effect of gut pH
on IgG transfer to the neonate indicated
that acidic pH was not necessary; non-
specific uptake of ligand into the cell was
adequate (1).
Despite underlying doubts about the
physiologic relevance of surface-displayed
receptor, it proved virtually impossible to
perform in vitro studies of IgG uptake by
cultured cells unless the medium was made
acidic. Uptake at physiologic pH was near
nil. Thus, workers proceeded to exploit
IgG uptake at low pH by surface recep-
tors in attempts to understand the subse-
quent steps in IgG endocytosis. A hand-
ful of strategies were used. Some experi-
ments were performed with adherent cells
such as the Madin–Darby Canine Kidney
cells wherein IgG transport was followed
after uptake in pH6 medium [e.g., Ref.
(2)]. More recently, both IgG and FcRn
have been mutated to manifest high affin-
ity for one another at physiological pH, so
that uptake of IgG by the surface receptors
of these cells can be studied at physio-
logical pH without resorting to a low-pH
uptake step [e.g., Ref. (3)]. In the neonatal
rat, gut IgG trafficking has been followed
after instillation of pH6 ligand into the gut
lumen [e.g., Ref. (4)].
The last two decades have witnessed a
spate of studies describing the intracellu-
lar trafficking that follows ligand uptake by
surface receptors [14 papers from multi-
ple laboratories in 18 years; see citations in
Ref. (5)]. By ignoring alternative pathways,
these studies appear to assume that this
pathway is the major if not the only uptake
pathway. They seem to ignore the pos-
sibility that this surface-receptor-initiated
pathway may be different and distinct from
a pathway that ensues after ligand bind-
ing to the receptor in the acidic endosome
subsequent to non-specific pinocytosis of
ligand. The latter pathway, first hypothe-
sized by Brambell in his original formula-
tion, has not yet been studied in vitro in
isolated cells. Yet, this pathway is almost
certainly the one utilized in the IgG degra-
dation pathway and in the yolk sac trans-
port pathway. And, there are solid reasons
to believe that it is the pathway used for
transport across the neonatal gut in mice
and rats.
So,what accounts for ignoring this path-
way for two decades, the pathway that
begins with non-specific uptake of lig-
and and receptor recognition of ligand in
acidic endosomes? Why has attention been
directed solely at the pathway following lig-
and binding to surface-expressed receptor?
The literature is not helpful in answering
why a more direct approach has not been
taken, why it has not been possible to learn
how acidic endosomes take up IgG that
has been non-specifically endocytosed and
how FcRn then moves its ligand across the
cell. Perhaps, it is enough for an essay of this
sort, one person’s opinion, to point out that
we workers in the field have passed over an
important question, and the whole story of


























































FcRn transport will not be readily under-
stood unless we return to basic experiments
and answer these fundamental questions.
I invite my colleagues to respond to this
challenge.
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